Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 16/20 | 0.83 |
| ▸ | BCL2 | P10415 | 5/20 | 0.83 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.83 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.54 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29928296 | 0.91 | MCL1 (1.00) | MCL1BCL2BCL2L1ALBBAD | |
| SCHEMBL29928106 | 0.89 | MCL1 (0.82) | MCL1BCL2BCL2L1ALB | |
| SCHEMBL22436900 | 0.89 | MCL1 (0.66) | MCL1BCL2BCL2L1ALB | |
| SCHEMBL15622733 | 0.83 | MCL1 (0.85) | MCL1BCL2BCL2L1ALBBAD | |
| SCHEMBL24773770 | 0.83 | MCL1 (0.59) | MCL1BCL2BCL2L1ALBBAD | |
| SCHEMBL22436759 | 0.82 | MCL1 (0.57) | MCL1BCL2BCL2L1ALBGPR17 | |
| SCHEMBL15622980 | 0.82 | MCL1 (0.76) | MCL1BCL2BCL2L1ALBGPR17 | |
| SCHEMBL24745269 | 0.82 | MCL1 (0.58) | MCL1BCL2BCL2L1ALB | |
| SCHEMBL15622867 | 0.81 | MCL1 (0.82) | MCL1BCL2BCL2L1ALBGPR17 | |
| SCHEMBL15622598 | 0.80 | MCL1 (0.80) | MCL1BCL2BCL2L1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440923-B2 | Substituted macrocyclic indole derivatives | FOXM1, CCND2, CCNI | MCL1 53/4885BCL2 635/4885BCL2L1 715/4885 |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | CCNT2, CCNL2, CCND2 | MCL1 26/4885BCL2 430/4885BCL2L1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.